---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-006898"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2023-03-16T23:59:59+00:00"
generated_at: "2026-06-18T00:22:06.168367+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AcelRx sells DSUVIA/DZUVEO assets to Vertical Pharma for up to $116.5M milestones plus royalties

## Summary
- AcelRx to sell DSUVIA/DZUVEO sufentanil tablet to Vertical Pharma; gets up to $116.5M in sales milestones and 15% net sales royalty.
- 75% of DoD net sales under marketing agreement; rights revert if Buyer fails to commercialize by July 1, 2023.
- Aguettant amendments: EUR 1.5M payment to AcelRx, termination of sales milestones, and supply restructuring.
- Terminates Catalent site readiness and commercial supply agreements; equipment to be removed from Catalent's site.

## SEC filing metadata
- accession: 0001437749-23-006898
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2023-03-16T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/0001437749-23-006898-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774923006898/acrx20230315_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-006898
- JSON: https://secwatch.observer/filing/0001437749-23-006898.json
- Plain text: https://secwatch.observer/filing/0001437749-23-006898.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.